SCHEMBL1338392

SCHEMBL1338392

CCOC(=O)c1nc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)cs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.42
▸ CDC7 O00311 1/20 0.40
▸ DBF4 Q9UBU7 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ GABRA2 P47869 7/20 0.38
▸ GABRB2 P47870 7/20 0.38
▸ TSHR P16473 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ EIF4E P06730 2/20 0.38
▸ CNR1 P21554 2/20 0.38
▸ CNR2 P34972 2/20 0.38
▸ LMNA P02545 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338811 0.86 RAB9A (0.43) MAPTCDC7DBF4KDM4EGABRA2
SCHEMBL1336976 0.84 TRIM24 (0.41) MAPTKDM4ENPC1POLBRAB9A
SCHEMBL1337288 0.84 GABRA1 (0.41) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1338929 0.84 POLB (0.39) MAPTCDC7DBF4KDM4EGABRA2
SCHEMBL1339176 0.83 EIF4E (0.39) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1339161 0.83 EIF4E (0.39) KDM4ENPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL1338398 0.83 ALPL (0.54) MAPTTSHRNPC1POLBRAB9A
SCHEMBL1339432 0.83 CNR1 (0.40) KDM4ENPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL1339436 0.82 EIF4E (0.38) KDM4ENPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL3256818 0.82 EIF4E (0.39) KDM4ENPC1RAB9ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 MAPT 2476/4885CDC7 2298/4885DBF4 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback